Short Interest in Idorsia Ltd (OTCMKTS:IDRSF) Increases By 53.6%

Idorsia Ltd (OTCMKTS:IDRSF) was the target of a significant growth in short interest during the month of September. As of September 30th, there was short interest totaling 1,498,100 shares, a growth of 53.6% from the September 15th total of 975,400 shares. Based on an average daily trading volume, of 700 shares, the short-interest ratio is presently 2,140.1 days. Based on an average daily trading volume, of 700 shares, the short-interest ratio is presently 2,140.1 days.

Idorsia Price Performance

Idorsia stock opened at $4.50 on Friday. The firm has a 50 day simple moving average of $4.28 and a 200-day simple moving average of $2.86. Idorsia has a 1-year low of $0.70 and a 1-year high of $5.82.

Analyst Ratings Changes

A number of equities analysts recently weighed in on the stock. Deutsche Bank Aktiengesellschaft restated a “hold” rating on shares of Idorsia in a research report on Friday, August 22nd. HC Wainwright upgraded Idorsia from a “neutral” rating to a “buy” rating in a report on Monday, September 15th. One research analyst has rated the stock with a Buy rating and one has issued a Hold rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy”.

Idorsia Company Profile

Idorsia Ltd, a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for unmet medical needs in Switzerland. The company has a clinical development pipeline that cover various therapeutic areas, including CNS, cardiovascular, and immunological disorders, as well as orphan diseases.